BioLine RX (Israel) Investor Sentiment

BLRX Stock  ILS 8.10  0.10  1.25%   
About 62% of BioLine RX's investor base is looking to short. The analysis of current outlook of investing in BioLine RX suggests that many traders are alarmed regarding BioLine RX's prospects. The current market sentiment, together with BioLine RX's historical and current headlines, can help investors time the market. In addition, many technical investors use BioLine RX stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Should You Buy BioLine RX Ltd - ADR Stock Monday Morning - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx Scheduled to Post Earnings on Tuesday - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
BioLine RX Ltd - ADR Up 1.69 percent in Premarket Trading - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx secures new patent for motixafortide production By Investing.com - Investing.com Australia
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx Stock Rating Reaffirmed by HC Wainwright - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
HC Wainwright Reiterates Buy Rating for BioLineRx - AmericanBankingNEWS
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent S...
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx to present new data on stem cell treatment at 2024 Tandem Meetings - Investing.com Austral...
Google News at Macroaxis
over six months ago at news.google.com         
Short Interest in BioLineRx Ltd. Rises By 96.2 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
BioLineRx Ltd. Sees Significant Drop in Short Interest - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
BioLineRx Weighing Aphexdas Breakthrough Against Financial Challenges - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
BLRX A Series of Fortunate Events - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Appel aux bnfices BioLineRx annonce lapprobation par la FDA ... - Investing.com France
Google News at Macroaxis
over a year ago at news.google.com         
BioLineRx Shares Rise 12 percent After Licensing Agreement for Motixafortide - MarketWatch
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about BioLine RX that are available to investors today. That information is available publicly through BioLine media outlets and privately through word of mouth or via BioLine internal channels. However, regardless of the origin, that massive amount of BioLine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioLine RX news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioLine RX relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioLine RX's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioLine RX alpha.

BioLine RX Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for BioLine Stock analysis

When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities